Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCTP | Q9UKL6 | 12/20 | 0.85 |
| ▸ | STARD10 | Q9Y365 | 6/20 | 0.85 |
| ▸ | STARD7 | Q9NQZ5 | 1/20 | 0.85 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1233504 | 0.92 | PCTP (1.00) | PCTPSTARD10STARD7GPR27LMNA | |
| SCHEMBL1234613 | 0.88 | PCTP (1.00) | PCTPSTARD10STARD7LMNAKDM4E | |
| SCHEMBL4554977 | 0.84 | PCTP (0.80) | PCTPSTARD10STARD7LMNAKDM4E | |
| SCHEMBL1233511 | 0.84 | PCTP (1.00) | PCTPSTARD10STARD7LMNAPOLB | |
| SCHEMBL1235844 | 0.84 | PCTP (1.00) | PCTPSTARD10STARD7GPR27LMNA | |
| SCHEMBL1235180 | 0.82 | PCTP (1.00) | PCTPSTARD10STARD7LMNAPOLB | |
| SCHEMBL1233510 | 0.82 | PCTP (1.00) | PCTPSTARD10STARD7LMNAKDM4E | |
| SCHEMBL1235205 | 0.82 | PCTP (1.00) | PCTPSTARD10STARD7POLB | |
| SCHEMBL13453566 | 0.81 | PCTP (0.83) | PCTPSTARD10STARD7LMNAKDM4E | |
| SCHEMBL1235093 | 0.80 | PCTP (1.00) | PCTPSTARD10STARD7LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264756-A1 | Phosphatidylcholine Transfer Protein Inhibitors | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264756-A1 | Phosphatidylcholine Transfer Protein Inhibitors | PCTP, LCAT, CETP | PCTP 1/4885STARD10 1028/4885STARD7 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.